A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Clinical trial NCT00277498 · COMPLETED

Trial details

NCT number: NCT00277498
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Open Angle Glaucoma Ocular Hypertension

Start date: 2005-12-01
Enrollment: 528

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.